New Holiday Inn Coming to Columbus

Posted: Updated:
COLUMBUS -

The city of Columbus will soon have a new Holiday Inn hotel. The Republic reports Fishers-based Dora Hotel Co. plans to invest nearly $10 million to renovate and expand the existing Comfort Inn & Suites and rebrand it as the Holiday Inn Columbus.

The hotel is located across the street from the city's former Holiday Inn location, which became the Clarion Hotel and Conference Center in 2012 and is now vacant. That property has since been acquired by Columbus Regional Health and will be demolished and replaced with a new CRH facility.

The new hotel will feature 100 rooms, including 15 suites, a restaurant, bar, and more than 1,600 square feet of banquet space, according to the publication. Dora is partnering with InterContinential Hotels Group (NYSE: IHG) on the project.

Dora Hotel Co. President Tim Dora tells The Republic the new hotel will be viable for the next 40 to 50 years when complete. Among the amenities planned for the hotel are a first floor business center, complementary Wi-Fi and seating areas with charging stations.

The hotel is set to close to begin renovations on September 1. The Holiday Inn Columbus is scheduled to open in August 2018.

You can read more about the project and Holiday Inn's history in Columbus in The Republic.

  • Perspectives

    • How Managers Can Keep Millennials Happy

      There are more than 56 million Millennials either actively participating in the workforce, or searching for a job. With a number like this, it’s no surprise that Millennials have taken the workplace by storm. But what is surprising is how different this generation is from their predecessors. They rely heavily on technology and prefer to communicate via text or email rather than a traditional phone call. Managing millennial employees can be a challenge — how can executives...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • $25M Behavioral Hospital Coming to Central Indiana

      Danville-based Hendricks Regional Health is partnering with US HealthVest to develop a stand-alone behavioral center on the Hendricks campus in Plainfield. Known as the Indianapolis Behavioral Hospital, the facility will provide specialized inpatient and outpatient mental health care to patients of all ages.

    • How Managers Can Keep Millennials Happy

      There are more than 56 million Millennials either actively participating in the workforce, or searching for a job. With a number like this, it’s no surprise that Millennials have taken the workplace by storm. But what is surprising is how different this generation is from their predecessors. They rely heavily on technology and prefer to communicate via text or email rather than a traditional phone call. Managing millennial employees can be a challenge — how can executives...

    • Christel DeHaan to Retire as Christel House CEO

      One of the biggest names in philanthropy in Indiana is announcing her retirement. Christel House International Chief Executive Officer Christel DeHaan will remain board chair, but leave as CEO of the nonprofit she founded 20 years ago. The organization has named former Indianapolis Mayor Bart Peterson to be her successor. CHI's mission is to lift children out of poverty, and it has established learning centers at home in Indianapolis and abroad in Mexico, India, South Africa and...

    • Sturges, CBRE Splitting Up

      A long-time commercial real estate firm in Fort Wayne is going independent. CBRE | Sturges, which became affiliated with the global brand more than 20 years ago, will become Sturges Property Group at the end of this month. The firm was founded in 1975 and bills itself as largest full-service commercial and industrial real estate firm in the region. The shift, Sturges says, will...

    • Endocyte, Novartis Ink $2.1B Merger Agreement

      West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) has announced a merger agreement with a global pharmaceutical giant. The deal with Switzerland-based Novartis AG is valued at $2.1 billion and still requires shareholder approval. Until regulatory and other approvals are met, Endocyte will remain independent. The proposed merger of Endocyte into Novartis is slated to be complete in the first half of next year. Endocyte develops targeted cancer therapies and earlier this...